ES2082749T3 - Interaccion sinergica de interleucina-2 y arn de doble cadena. - Google Patents

Interaccion sinergica de interleucina-2 y arn de doble cadena.

Info

Publication number
ES2082749T3
ES2082749T3 ES88301821T ES88301821T ES2082749T3 ES 2082749 T3 ES2082749 T3 ES 2082749T3 ES 88301821 T ES88301821 T ES 88301821T ES 88301821 T ES88301821 T ES 88301821T ES 2082749 T3 ES2082749 T3 ES 2082749T3
Authority
ES
Spain
Prior art keywords
various
variums
lymphocines
dsrna
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88301821T
Other languages
English (en)
Inventor
William A Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HEM Pharmaceuticals Corp
Original Assignee
HEM Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HEM Pharmaceuticals Corp filed Critical HEM Pharmaceuticals Corp
Application granted granted Critical
Publication of ES2082749T3 publication Critical patent/ES2082749T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMBINACION SINERGICA INESPERADA ENTRE LINFOQUINAS Y DSRNAS QUE REDUCE DRAMATICAMENTE LAS DOSIS NECESARIAS DE LINFOQUINAS, ESPECIALMENTE IL-2 Y SIMULTANEAMENTE AMPLIA SU INTERVALO TERAPEUTICO EN EL TRATAMIENTO DE VARIOS TIPOS DE CANCERES, ENFERMEDADES VIRICAS U OTROS ESTADOS CORPORALES CARACTERIZADOS POR ESTADOS INMUNES DISRREGULADOS (POR EJEMPLO ENFERMEDADES AUTOINMUNES). COMBINACIONES ESPECIFICAS DE DSRNA MAS IL-2 AUMENTAN SIGNIFICATIVAMENTE LA SUPERVIVENCIA EN ANIMALES CON MELANOMA HUMANO, EN PARTE A CAUSA DEL AUMENTO PRODUCIDO POR EL DSRNA DE CELULAS MUERTAS ACTIVADAS POR LINFOQUINA (LAK) QUE SE FORMAN EN PRIMER LUGAR COMO RESPUESTA A LA EXPOSICION A IL-2. LA INVENCION TIENEN AMPLIA APLICABILIDAD EN EL CONTROL EFICAZ NO-TOXIDO DEL CANCER Y DE VARIAS INFECCIONES VIRICAS Y ENFREMEDADES DE INMUNORREGULACION HUMANAS.
ES88301821T 1987-03-03 1988-03-02 Interaccion sinergica de interleucina-2 y arn de doble cadena. Expired - Lifetime ES2082749T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2136887A 1987-03-03 1987-03-03

Publications (1)

Publication Number Publication Date
ES2082749T3 true ES2082749T3 (es) 1996-04-01

Family

ID=21803798

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88301821T Expired - Lifetime ES2082749T3 (es) 1987-03-03 1988-03-02 Interaccion sinergica de interleucina-2 y arn de doble cadena.

Country Status (19)

Country Link
EP (1) EP0281380B1 (es)
JP (1) JPH0713024B2 (es)
KR (1) KR960008009B1 (es)
CN (1) CN1054509C (es)
AT (1) ATE130760T1 (es)
AU (2) AU1256588A (es)
CA (1) CA1336810C (es)
DE (1) DE3854726T2 (es)
DK (1) DK113188A (es)
ES (1) ES2082749T3 (es)
FI (1) FI880961A7 (es)
IE (1) IE75895B1 (es)
IL (1) IL85603A (es)
NO (1) NO880946L (es)
NZ (1) NZ223720A (es)
PH (1) PH24467A (es)
PT (1) PT86879B (es)
RU (1) RU1836103C (es)
ZA (1) ZA881512B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA881639B (en) * 1987-03-23 1989-02-22 Hem Res Inc Treatment of human viral infection by dsrna combined with viral inhibitors
DE69021791T2 (de) * 1989-06-30 1996-05-02 American Cyanamid Co Verwendung eines phagozytise-aktievierenden Stoffes : LPS oder IL-2 zur Herstellung eines Arzneimittels zur Behandlung von Staphylococcus-aureus-Infektionen bei Kühen.
FR2768345B1 (fr) * 1997-09-17 2001-05-04 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale
FR2766715B1 (fr) * 1997-08-04 2001-02-16 Scras Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
FR2768344B1 (fr) * 1997-08-26 2001-02-16 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
BRPI9908967B1 (pt) 1998-03-20 2017-05-30 Benitec Australia Ltd processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
US10392444B2 (en) 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380200D1 (en) * 1982-09-16 1989-08-24 William Alvin Carter Anti-proliferative action of dsnras on tumor cells
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)

Also Published As

Publication number Publication date
PT86879A (pt) 1988-04-01
PH24467A (en) 1990-07-18
DK113188A (da) 1988-09-04
FI880961L (fi) 1988-09-04
NO880946L (no) 1988-09-05
ZA881512B (en) 1988-11-30
IE75895B1 (en) 1997-09-24
CN1032296A (zh) 1989-04-12
RU1836103C (ru) 1993-08-23
EP0281380A2 (en) 1988-09-07
AU1256588A (en) 1988-09-01
DE3854726T2 (de) 1996-07-25
IE880588L (en) 1988-09-03
CA1336810C (en) 1995-08-29
CN1054509C (zh) 2000-07-19
ATE130760T1 (de) 1995-12-15
DE3854726D1 (de) 1996-01-11
KR880010776A (ko) 1988-10-24
NZ223720A (en) 1991-07-26
JPH0713024B2 (ja) 1995-02-15
AU1618992A (en) 1992-08-06
FI880961A0 (fi) 1988-03-02
FI880961A7 (fi) 1988-09-04
IL85603A (en) 1993-05-13
NO880946D0 (no) 1988-03-03
JPS63295514A (ja) 1988-12-01
IL85603A0 (en) 1988-08-31
DK113188D0 (da) 1988-03-02
EP0281380B1 (en) 1995-11-29
KR960008009B1 (ko) 1996-06-19
EP0281380A3 (en) 1989-09-27
PT86879B (pt) 1992-05-29

Similar Documents

Publication Publication Date Title
ES2086623T3 (es) Azaheterociclilmetil-cromanos como principios activos para el tratamiento de enfermedades del sistema nervioso central.
ES2099211T3 (es) Conjugados citomoduladores de miembros de parejas de union especifica.
ES2033170B1 (es) Cebo envenenado para la erradicacion de insectos nocivos.
DK113188D0 (da) Synergistisk praeparat indeholdende lymfokiner og dsrna
ES2118058T3 (es) Factor de crecimiento de las celulas t.
ES2043901T3 (es) Adyuvante para la terapia inmunologica del cancer.
AR034954A1 (es) Utilizacion de lhrh-antagonistas en dosis que no producen la castracion, para la mejora de la inmunidad mediada por las celulas t
MXPA04007491A (es) Tratamiento profilactico y terapeutico de infecciones y otras enfermedades con compuestos inmunoefectores.
ES2171169T3 (es) Uso de celulas tall-104 modificadas para tratar cancer y enfermedades virales.
ES2056054T3 (es) Uso de linfocitos t activados para preparar una composicion farmaceutica para el tratamiento del sida.
ES2151891T3 (es) Derivados de ciclohexano sustituidos con imidazolilo.
MX2025011694A (es) Anticuerpos de quimiocina cxc pan-elr+ para el tratamiento de la hidradenitis supurativa
BE602374A (fr) Clapet de retenue ne s'obstruant pas.
FR1528M (fr) Agents thérapeutiques anthelminthiques.
GT197329432A (es) Procedimiento de obtencion de formas farmaceuticas de efectoretardado
清水茂 Vegetable breeding works
CU21028L (en) Compounds of substituted halogenacetylides
AR061949A1 (es) Uso de nitro derivados de flavonas como agentes inductores de apoptosis para la preparacion de un medicamento
FR2445M (fr) Nouveaux dérivés de la pipérazine, utilisables en thérapeutique.
FR1285867A (fr) Vanne de retenue ne s'engorgeant pas
FR1237515A (fr) Appareil alimenté par accumulateur, en particulier lampe de poche
ES82817U (es) Percha
ECSP910730A (es) Agente preventivo contra una enfermedad infecciosa de los crustaceos
GT196200276A (es) O,o dialquilfosfintioimidato.
AU592561A (en) Flat, tapered horseshoe type return spring and brake shoe assembly

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 281380

Country of ref document: ES